Skip to content
★ Sign in to follow
QuantaMatrix Inc. logo

QuantaMatrix Inc. Stock: price and insider trades · South Korea

퀀타매트릭스

KR·Mcap ₩45.4BHealth Care

No insider purchase over the last 90 days. The latest, by 권성훈, was filed 26 Jan 2026.

QuantaMatrix Inc.: what insiders have been doing

QuantaMatrix Inc. is a Health Care company. Its directors and officers file their transactions with DART (FSS). The last twelve months, up to 2 November 2026, brought 7 filings signed by 4 insiders.

Both sides are active: 2 purchases and 3 sales, from 2 insiders and 3 insiders respectively. The amount is not disclosed for 5 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price.

The clock since the last published purchase (26 January 2026) now reads 288 days. Between a trade and the moment it shows up on DART (FSS), the median delay is 7 days. This delay matters because a trade only becomes useful information once it is public. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.

Compared with its exchange (2,655 companies, median 7 filings), a count of 7 filings is typical. The full history, which starts in 2021, counts 3 purchases against 11 sales.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.

Insider Decl.
21
Thresholds
n/a
Buy Volume
€4M
3 ops. · all time
Sell Volume
€6M
11 ops. · all time

Who traded when

BuySale
에즈라채리터블트러스트3 sales
권성훈1 buy1 sale
타이거자산운용투자일임2 sales
펜타스톤 3호 신기술투자조합1 buy
Fundamental score
Ranked 24,548 of 26,911 companies
20.3
score / 100
Value
6
Quality
34
FCF yld-35%
Earn yld-43%
EV/EBITDA·
ROE-97%
Gross mgn44%
Net mgn·
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩2,255
Analyst consensus
·
Income statement
Revenue₩3.7B
Gross profit₩1.6B44% margin
EBITDA-₩15.6B-424% margin
Net income-₩19.5B-527.6% margin
Valuation
Beta0.21
Balance sheet & cash
Market cap₩45.4B
Total debt₩9.6B
Free Cash Flow-₩15.7B
Debt / Equity19%
Profitability & ownership
ROE-96.9%
ROA-30.3%
% insiders27.4%
% institutions0.2%
Last declaration on 1 April 2026
Declarations21 total

21 of 21 declarations

About QuantaMatrix Inc.

퀀타매트릭스 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in developing innovative solutions for the medical sector.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations